ALDH1 mRNA: Presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia

Neurobiology of Disease

Volumn 14, Issue 3, 2003, Pages 637-647

  Galter, Dagmar ^a   Buervenich, Silvia ^a   Carmine, Andrea ^a   Anvret, Maria ^a,b   Olson, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Dopamine transporter; In situ hybridization; Substantia nigra; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; ENOLASE; ISOENZYME; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; CELL ASSAY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REDUCTION; SCHIZOPHRENIA; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0348109455     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.09.001     Document Type: Article

References (53)

1. Braak H., Braak E., Yilmazer D., de Vos R.A., Jansen E.N., Bohl J., Jellinger K. Amygdala pathology in Parkinson's disease. Acta Neuropathol. (Berl.). 88:1994;493-500.
2. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl. 46:1995;15-31.
3. Braak H., de Vos R.A., Jansen E.N., Bratzke H., Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's disease. Prog. Brain Res. 117:1998;267-285.
4. Buckland P.R., O'Donovan M.C., McGuffin P. Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl.). 108:1992;98-102.
5. Buervenich S., Carmine A., Arvidsson M., Xiang F., Zhang Z., Sydow O., Jonsson E.G., Sedvall G.C., Leonard S., Ross R.G., Freedman R., Chowdari K.V., Nimgaonkar V.L., Perlmann T., Anvret M., Olson L. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 96:2000;808-813.
6. Buervenich S., Sydow O., Carmine A., Zhang Z., Anvret M., Olson L. Alcohol dehydrogenase alleles in Parkinson's disease. Mov. Disord. 15:2000;813-818.
7. Calne D.B. Developments in the pharmacology and therapeutics of parkinsonism. Ann. Neurol. 1:1977;111-119.
8. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1957;1200-1201.
9. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia new evidence . Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
10. Collins M.A. Neuroamine condensations in human subjects. Adv. Exp. Med. Biol. 126:1980;87-102.
11. Corrodi H., Jonsson G. Fluorescence methods for the histochemical demonstration of monoamines. 4. Histochemical differentiation between dopamine and noradrenaline in models. J. Histochem. Cytochem. 13:1965;484-487.
12. Cottingham S.L., Pickar D., Shimotake T.K., Montpied P., Paul S.M., Crawley J.N. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration. Cell Mol. Neurobiol. 10:1990;41-50.
13. Dagerlind A., Friberg K., Bean A.J., Hökfelt T. Sensitive mRNA detection using unfixed tissue combined radioactive and non-radioactive in situ hybridization histochemistry . Histochemistry. 98:1992;39-49.
14. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:(Pt. 8):1999;1437-1448.
15. Dostert P., Strolin B.M., Dordain G. Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J. Neural Transm. 74:1988;61-74.
16. Doudet D.J., Chan G.L., Holden J.E., Morrison K.S., Wyatt R.J., Ruth T.J. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology. 36:1997;363-371.
17. Duester G. 2001. Genetic dissection of retinoid dehydrogenases. Chem. Biol. Interact. 130-132, 469-480.
18. Eriksson C.J. Regulation of acetaldehyde metabolism during ethanol oxidation in perfused rat liver. Adv. Exp. Med. Biol. 85A:1977;225-236.
19. Esterbauer H., Zollner H., Lang J. Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem.J. 228:1985;363-373.
20. Farmer A.E., McGuffin P. The pathogenesis and management of schizophrenia. Drugs. 35:1988;177-185.
21. Foster O.J., Biswas S., Lightman S.L. Neuropeptide Y and tyrosine hydroxylase mRNA levels in the locus coeruleus show similar increases after reserpine treatment. Neuropeptides. 18:1991;137-141.
22. Hartman R.D., Liaw J.J., He J.R., Barraclough C.A. Effects of reserpine on tyrosine hydroxylase mRNA levels in locus coeruleus and medullary A1 and A2 neurons analyzed by in situ hybridization histochemistry and quantitative image analysis methods. Brain Res. Mol. Brain Res. 13:1992;223-229.
23. Hjelle J.J., Petersen D.R. Metabolism of malondialdehyde by rat liver aldehyde dehydrogenase. Toxicol. Appl. Pharmacol. 70:1983;57-66.
24. Hornykiewicz O. Die topische lokalisation und das verhalten von noradrenalin und dopamin (3-hydroxytyramin) in der substantia nigra des normalen und parkinsonkranken menschen. Wien. Klin. Wochenschr. 75:1963;309-312.
25. Hsu L.C., Chang W.C., Yoshida A. Genomic structure of the human cytosolic aldehyde dehydrogenase gene. Genomics. 5:1989;857-865.
26. Impraim C., Wang G., Yoshida A. Structural mutation in a major human aldehyde dehydrogenase gene results in loss of enzyme activity. Am. J. Hum. Genet. 34:1982;837-841.
27. Kingsbury A.E., Marsden C.D., Foster O.J. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis an in situ hybridization study . Mov. Disord. 14:1999;206-218.
28. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., Burke W.J. Selective dopaminergic vulnerability 3,4-dihydroxyphenylacetaldehyde targets mitochondria . Free Radic. Biol. Med. 30:2001;924-931.
29. Li S.W., Lin T.S., Minteer S., Burke W.J. 3,4- Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical possible role in Parkinson's disease pathogenesis . Brain Res. Mol. Brain Res. 93:2001;1-7.
30. Liddon S.C., Satran R. Disulfiram (Antabuse) psychosis. Am. J. Psychiatry. 123:1967;1284-1289.
31. Maring J.A., Deitrich R.A., Little R. Partial purification and properties of human brain aldehyde dehydrogenases. J. Neurochem. 45:1985;1903-1910.
32. McCaffery P., Dräger U.C. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc. Natl. Acad. Sci. USA. 91:1994;7772-7776.
33. McCaffery P., Dräger U.C. Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. Adv. Exp. Med. Biol. 372:1995;173-183.
34. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., Montine T.J. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56:1997;866-871.
35. Morel P., Tallineau C., Pontcharraud R., Piriou A., Huguet F. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/ K+ ATPase in rat striatal synaptosomes. Neurochem. Int. 33:1998;531-540.
36. Murthy K.K. Psychosis during disulfiram therapy for alcoholism. J. Indian Med. Assoc. 95:1997;80-81.
37. Nagatsu T., Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett. 87:1988;178-182.
38. Parkinson J. An Essay on the Shaking Palsy. 1817;Sherwood, Neely & Jones, London.
39. Pasinetti G.M., Morgan D.G., Johnson S.A., Millar S.L., Finch C.E. Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine. J. Neurochem. 55:1990;1793-1799.
40. Pictet A., Spengler T. Über die bildung von isochinolin-derivaten durch die einwirkung von methylal auf phenyl-äthylamin, phenyl-alanin and tyrosin. Berl. Dtsch. Chem. Ges. 44:1911;2030-2036.
41. Scher J.M. Psychotic reaction to disulfiram. J. Am. Med. Assoc. 201:1967;1051.
42. Selley M.L. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25:1998;169-174.
43. Soto-Otero R., Mendez-Alvarez E., Sanchez-Sellero I., Cruz-Landeira A., Lopez-Rivadulla L.M. Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-beta-carboline by cigarette smoke. Neurosci. Lett. 298:2001;187-190.
44. Suzuki K., Mizuno Y., Yoshida M. Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain. Neurochem. Res. 15:1990;705-710.
45. Trétiakov C. Contribution à l'Etude de l'Anatomie Pathologique du Locus Niger de Soemmering avec Quelques Déductions Relatives à la Pathogénie des Troubles du Tonus Musculaire et de la Maladie de Parkinson. 1919;Thèse de Paris.
46. Wallén A., Zetterström R.H., Solomin L., Arvidsson M., Olson L., Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 253:1999;737-746.
47. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2701.
48. Yoshida A., Hsu L.C., Dave V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 46:1992;239-244.
49. Yoshida M., Niwa T., Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline the behavioral and biochemical changes . Neurosci. Lett. 119:1990;109-113.
50. Yoshida M., Ogawa M., Suzuki K., Nagatsu T. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Adv. Neurol. 60:1993;207-211.
51. Zetterström R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 276:1997;248-250.
52. Zetterström R.H., Solomin L., Mitsiadis T., Olson L., Perlmann T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol. Endocrinol. 10:1996;1656-1666.
53. Zetterström R.H., Williams R., Perlmann T., Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41:1996;111-120.